In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Tocagen Inc (NASDAQ: TOCA), with a price target of $30. The company’s shares closed on Friday at $15.59, close to its 52-week high of $15.80.
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 25.5% and a 52.9% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Tocagen Inc has an analyst consensus of Strong Buy, with a price target consensus of $22.17, which is a 42.2% upside from current levels. In a report issued on September 20, H.C. Wainwright also maintained a Buy rating on the stock with a $14.50 price target.
.
See today’s analyst top recommended stocks >>
Based on Tocagen Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $16.09 million. In comparison, last year the company had a GAAP net loss of $9.95 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy compan. It focuses on the development of product candidates designed to activate a patient’s immune system against their own cancer from within. It is in the business of discovery, development, and commercialization of products for the treatment of cancer.
